Session Title: Quick Fire Free Paper 4
Session Date/Time: Sunday 14/09/2014 | 08:00-10:00
Paper Time: 09:50
Venue: Boulevard B
First Author: : M.Mazen EGYPT
Co Author(s): : M. Soliman T. Macky G. Ragab
To assess the safety and efficacy of intravitreal infliximab, an anti-tumor necrosis factor antibody, for sight-threatening relapsing posterior uveitis in Behçet disease.
Ophthalmology Department, Cairo University Hospitals, Cairo, Egypt.
Three consecutive intravitreal injections of infiximab (1 mg/0.05 ml) 6 weeks apart were given to 20 patients with relapsing posterior uveitis in Behcet’s Disease. Best corrected visual acuity (BCVA), intraocular pressure (IOP), vitritis (graded 0-4) and posterior segment vasculitis (presence or absence) were assessed at baseline, day 1 and 2, 4, 6, 8, 12, and 18 weeks post-injections. Optical Coherence Tomography (OCT) and Electroretinogram (ERG) were done at baseline and 4, 12, and 18 weeks. Fluorescein angiography (FA) was done at baseline and 4 weeks.
There were no ocular and/or extra-ocular side effects observed during the study period. Mean BCVA at baseline (0.85LogMAR) improved significantly by week 2 (0.55 LogMAR, P < 0.05) and continued to improve (0.40LogMAR, P< 0.05) by the end of follow up. Profound decrease in vitiris grade from mean 2.8 at baseline to 0.3 by the end of follow up (P < 0.05). Retinal vasculitis was present in 15 patients and cleared in 13 patients by the end of follow up (P< 0.05).Mean central macular thickness decreased significantly from baseline 318µ to 180µ by the end of follow up (P< 0.05). No electrophysiological changes were observed during the study period.
These findings suggest that intravitral infliximab is safe and effective in the treatment of relapsing posterior uveitis in Behcet’s Disease and should be considered when systemic use of infiximab is contraindicated, not feasible, or not effective.